Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Highlights

Highlights of This Issue

DOI:  Published July 2018
  • Article
  • Info & Metrics
  • PDF
Loading

5FU-Enhanced PDT for Human Actinic Keratoses

See article by Maytin et al., p. 3026

Actinic keratoses (AK) are very common premalignant skin lesions (presquamous cell carcinoma) in patients with chronic sun damage. Recently, physicians have been empirically combining two treatment approaches, topical 5-fluorouracil (5FU) and photodynamic therapy (PDT), but without any scientific basis. In a mechanistic clinical study using surface fluorimetry and skin biopsies, Maytin and colleagues show that sequential 5FU and PDT improves AK clearance by upregulating mitochondrial heme enzymes, increasing target photosensitizer (protoporphyrin IX) expression, and increasing proapoptotic p53. The results provide a scientific rationale for combining two FDA-approved treatments in an effective, practical approach that reduces cutaneous precancer burden.

KEAP1-NFE2L2 Mutations in Lung Cancer

See article by Frank et al., p. 3087

Besides therapeutically targetable mutations in signal transduction pathways, mutations related to the KEAP1/NRF2-pathway are involved in malignant transformation in various cancers, including lung cancer. Based on the NGS-analysis of a large cohort of NSCLC patients, Frank and colleagues show that mutations in KEAP1 and NRF2 occurred nearly mutually exclusive even though strongly linked functionally. They are also associated with different histologies, clinical characteristics, and co-occurring molecular aberrations. Thus, patients with KEAP1- or NRF2-mutations are a heterogenous group. This work argues against a driver function of these mutations but suggests a pivotal role in chemotherapy resistance.

Novel Resistance Mechanisms to Osimertinib in NSCLC Patients

See article by Yang et al., p. 3097

Around 50% of non-small cell lung cancer (NSCLC) patients receiving first-generation EGFR inhibitors develop resistance by T790M mutation. Osimertinib has proven effective in overcoming T790M mutation; however, resistance inevitably develops. Yang and colleagues surveyed 416 cancer-related genes in 93 NSCLC patients who progressed on osimertinib by next-generation sequencing (NGS). EGFR mutation on G796/C797, L792 or L718/G719 residues were identified in approximately 1/3 of the patients; further, resistance mechanisms were functionally studied in vitro. In EGFR nonmutated patients, MET, KRAS, and PIK3CA mutations were discovered. This study uncovers novel osimertinib-resistant mechanisms using cell-free DNA-based liquid biopsy and provides grounds for future therapeutic strategies.

ZIP4 Regulates Pancreatic Cancer Invasion and Metastasis

See article by Liu et al., p. 3186

Dysregulated zinc transport is involved in many malignancies, including pancreatic cancer, and it promotes tumor growth. To further understand the mechanism of zinc transporter-mediated cancer progression, Liu and colleagues used genetic inactivation and rescue assays in human pancreatic cancer cells and mouse models to demonstrate that a zinc importer ZIP4 promotes pancreatic cancer migration and invasion through decreasing ZO-1 and claudin-1 via activation of ZEB1, leading to upregulation of their targets FAK and Paxillin. These findings suggest a novel signaling pathway initiated by ZIP4 controlling pancreatic cancer invasiveness and metastasis, and may be a new therapeutic target for this devastating disease.

  • ©2018 American Association for Cancer Research.
PreviousNext
Back to top
Clinical Cancer Research: 24 (13)
July 2018
Volume 24, Issue 13
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
Citation Tools
Highlights of This Issue
Clin Cancer Res July 1 2018 (24) (13) 2977;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Clin Cancer Res July 1 2018 (24) (13) 2977;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • 5FU-Enhanced PDT for Human Actinic Keratoses
    • KEAP1-NFE2L2 Mutations in Lung Cancer
    • Novel Resistance Mechanisms to Osimertinib in NSCLC Patients
    • ZIP4 Regulates Pancreatic Cancer Invasion and Metastasis
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Highlights of This Issue
  • Highlights of This Issue
  • Highlights of This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement